---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-041723"
form_type: "8-K"
ticker: "AVR"
cik: "0002011514"
company_name: "Anteris Technologies Global Corp."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:39:14.238615+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Anteris reports Q3 2025 cash burn; FDA OK to start PARADIGM trial in US

## Summary
- FDA approved U.S. recruitment for PARADIGM Trial in Nov 2025; first patients treated in Denmark in Oct 2025.
- Q3 2025: R&D expenses $16.8M, SG&A $5.8M; net operating cash outflow 9M $59.3M.
- Cash and cash equivalents $9.1M as of Sep 30, 2025.
- IPO net proceeds $80M used: $52.7M for DurAVR development, $18.3M for debt repayment and working capital.
- Related party payments in Q3: $515k (director fees, CEO, CFO remuneration).

## SEC filing metadata
- accession: 0001140361-25-041723
- form_type: 8-K
- ticker: AVR
- cik: 0002011514
- company_name: Anteris Technologies Global Corp.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2011514/000114036125041723/0001140361-25-041723-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2011514/000114036125041723/ef20058755_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-041723
- JSON: https://secwatch.observer/filing/0001140361-25-041723.json
- Plain text: https://secwatch.observer/filing/0001140361-25-041723.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.